Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:10603098rdf:typepubmed:Citationlld:pubmed
pubmed-article:10603098lifeskim:mentionsumls-concept:C0023911lld:lifeskim
pubmed-article:10603098lifeskim:mentionsumls-concept:C0017920lld:lifeskim
pubmed-article:10603098pubmed:dateCreated2000-1-6lld:pubmed
pubmed-article:10603098pubmed:abstractTextGlycogen storage disease (GSD) types I, III, and IV can be associated with severe liver disease. The possible development of hepatocellular carcinoma and/or hepatic failure make these GSDs potential candidates for liver transplantation. Early diagnosis and initiation of effective dietary therapy have dramatically improved the outcome of GSD type I by reducing the incidence of liver adenoma and renal insufficiency. Nine type I and 3 type III patients have received liver transplants because of poor metabolic control, multiple liver adenomas, or progressive liver failure. Metabolic abnormalities were corrected in all GSD type I and type III patients, while catch-up growth was reported only in two patients. Whether liver transplantation results in reversal and/or prevention of renal disease remains unclear. Neutropenia persisted in both GSDIb patients post liver transplantation necessitating continuous granulocyte colony stimulating factor treatment. Thirteen GSD type IV patients were liver transplanted because of progressive liver cirrhosis and failure. All but one patient have not had neuromuscular or cardiac complications during follow-up periods for as long as 13 years. Four have died within a week and 5 years after transplantation. Caution should be taken in selecting GSD type IV candidates for liver transplantation because of the variable phenotype, which may include life-limiting extrahepatic manifestations. It remains to be evaluated, whether a genotype-phenotype correlation exists for GSD type IV, which may aid in the decision making. CONCLUSION: Liver transplantation should be considered for patients with glycogen storage disease who have developed liver malignancy or hepatic failure, and for type IV patients with the classical and progressive hepatic form.lld:pubmed
pubmed-article:10603098pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10603098pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10603098pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10603098pubmed:languageenglld:pubmed
pubmed-article:10603098pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10603098pubmed:citationSubsetIMlld:pubmed
pubmed-article:10603098pubmed:statusMEDLINElld:pubmed
pubmed-article:10603098pubmed:monthDeclld:pubmed
pubmed-article:10603098pubmed:issn0340-6199lld:pubmed
pubmed-article:10603098pubmed:authorpubmed-author:StarzlT ETElld:pubmed
pubmed-article:10603098pubmed:authorpubmed-author:HugGGlld:pubmed
pubmed-article:10603098pubmed:authorpubmed-author:ChenY TYTlld:pubmed
pubmed-article:10603098pubmed:authorpubmed-author:BarnardJJlld:pubmed
pubmed-article:10603098pubmed:authorpubmed-author:DhawanAAlld:pubmed
pubmed-article:10603098pubmed:authorpubmed-author:LachauxAAlld:pubmed
pubmed-article:10603098pubmed:authorpubmed-author:EmondJJlld:pubmed
pubmed-article:10603098pubmed:authorpubmed-author:BynonJ SJSlld:pubmed
pubmed-article:10603098pubmed:authorpubmed-author:HaagsmaE BEBlld:pubmed
pubmed-article:10603098pubmed:authorpubmed-author:SmitG PGPlld:pubmed
pubmed-article:10603098pubmed:authorpubmed-author:ArnaoutWWlld:pubmed
pubmed-article:10603098pubmed:authorpubmed-author:MaternDDlld:pubmed
pubmed-article:10603098pubmed:issnTypePrintlld:pubmed
pubmed-article:10603098pubmed:volume158 Suppl 2lld:pubmed
pubmed-article:10603098pubmed:ownerNLMlld:pubmed
pubmed-article:10603098pubmed:authorsCompleteYlld:pubmed
pubmed-article:10603098pubmed:paginationS43-8lld:pubmed
pubmed-article:10603098pubmed:dateRevised2011-10-31lld:pubmed
pubmed-article:10603098pubmed:meshHeadingpubmed-meshheading:10603098...lld:pubmed
pubmed-article:10603098pubmed:meshHeadingpubmed-meshheading:10603098...lld:pubmed
pubmed-article:10603098pubmed:meshHeadingpubmed-meshheading:10603098...lld:pubmed
pubmed-article:10603098pubmed:meshHeadingpubmed-meshheading:10603098...lld:pubmed
pubmed-article:10603098pubmed:meshHeadingpubmed-meshheading:10603098...lld:pubmed
pubmed-article:10603098pubmed:meshHeadingpubmed-meshheading:10603098...lld:pubmed
pubmed-article:10603098pubmed:meshHeadingpubmed-meshheading:10603098...lld:pubmed
pubmed-article:10603098pubmed:meshHeadingpubmed-meshheading:10603098...lld:pubmed
pubmed-article:10603098pubmed:meshHeadingpubmed-meshheading:10603098...lld:pubmed
pubmed-article:10603098pubmed:meshHeadingpubmed-meshheading:10603098...lld:pubmed
pubmed-article:10603098pubmed:meshHeadingpubmed-meshheading:10603098...lld:pubmed
pubmed-article:10603098pubmed:meshHeadingpubmed-meshheading:10603098...lld:pubmed
pubmed-article:10603098pubmed:meshHeadingpubmed-meshheading:10603098...lld:pubmed
pubmed-article:10603098pubmed:year1999lld:pubmed
pubmed-article:10603098pubmed:articleTitleLiver transplantation for glycogen storage disease types I, III, and IV.lld:pubmed
pubmed-article:10603098pubmed:affiliationDepartment of Pediatrics, Duke University Medical Center, P.O. Box 3528, Durham, NC 27710, USA.lld:pubmed
pubmed-article:10603098pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:10603098pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
pubmed-article:10603098pubmed:publicationTypeReviewlld:pubmed
pubmed-article:10603098pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10603098lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10603098lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10603098lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10603098lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10603098lld:pubmed